CA2728232C - Cell lysis reagent for isolation of rna - Google Patents
Cell lysis reagent for isolation of rna Download PDFInfo
- Publication number
- CA2728232C CA2728232C CA2728232A CA2728232A CA2728232C CA 2728232 C CA2728232 C CA 2728232C CA 2728232 A CA2728232 A CA 2728232A CA 2728232 A CA2728232 A CA 2728232A CA 2728232 C CA2728232 C CA 2728232C
- Authority
- CA
- Canada
- Prior art keywords
- reagent
- constitutes
- rna
- cellular material
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 79
- 230000006037 cell lysis Effects 0.000 title description 3
- 238000002955 isolation Methods 0.000 title description 3
- 239000000463 material Substances 0.000 claims abstract description 21
- 230000001413 cellular effect Effects 0.000 claims abstract description 20
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960002897 heparin Drugs 0.000 claims abstract description 15
- 229920000669 heparin Polymers 0.000 claims abstract description 15
- 239000002738 chelating agent Substances 0.000 claims abstract description 11
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 11
- 239000000872 buffer Substances 0.000 claims abstract description 10
- 229910001508 alkali metal halide Inorganic materials 0.000 claims abstract description 8
- 150000008045 alkali metal halides Chemical class 0.000 claims abstract description 8
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 239000003599 detergent Substances 0.000 claims description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 11
- 239000007983 Tris buffer Substances 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004889 salicylic acid Drugs 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 3
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 229910001514 alkali metal chloride Inorganic materials 0.000 claims description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 229960003540 oxyquinoline Drugs 0.000 claims description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 1
- FRCAFNBBXRWXQA-XRIGFGBMSA-N L-Histidinol dihydrochloride Chemical compound Cl.Cl.OC[C@@H](N)CC1=CN=CN1 FRCAFNBBXRWXQA-XRIGFGBMSA-N 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- -1 poly(oxyethylene) Polymers 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Chemical class OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical class OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000003022 phthalic acids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
RNA is extracted from cellular material with a reagent that includes heparin, a reducing agent to reduce disulfide bonds, a chelating agent, a buffer, and an alkali metal halide. The reagent does not require the use of organic solvents, and the reagent allows extraction to be performed in a relatively short period of time in comparison to the prior art.
Description
CELL LYSIS REAGENT FOR ISOLATION OF
RNA
BACKGROUND OF THE INVENTION
1. Field of the Invention [0002] This invention resides in the field of extracting RNA from eukaryotic cells.
2. Description of the Prior Art [0003] The extraction of RNA from cellular material is an important step in a variety of laboratory procedures for diagnostics, therapy, and research. Extraction is typically achieved by use of an extraction reagent, and to be effective for this purpose, the reagent should extract the RNA, preferably by cell lysis, without disrupting the cell nuclei. An effective reagent should also inhibit any enzymes in the material that degrade RNA, such as RNAses, so that the RNA remains intact both during and after extraction. Further, the reagent should disrupt RNA-binding proteins to cause the proteins to release the RNA and to make the proteins incapable of further binding, even when the proteins are still in contact with the RNA. Still further, the reagent should disrupt any secondary or tertiary RNA structures, for example by chelation, so that the RNA can be used in subsequent processes and reactions.
RNA
BACKGROUND OF THE INVENTION
1. Field of the Invention [0002] This invention resides in the field of extracting RNA from eukaryotic cells.
2. Description of the Prior Art [0003] The extraction of RNA from cellular material is an important step in a variety of laboratory procedures for diagnostics, therapy, and research. Extraction is typically achieved by use of an extraction reagent, and to be effective for this purpose, the reagent should extract the RNA, preferably by cell lysis, without disrupting the cell nuclei. An effective reagent should also inhibit any enzymes in the material that degrade RNA, such as RNAses, so that the RNA remains intact both during and after extraction. Further, the reagent should disrupt RNA-binding proteins to cause the proteins to release the RNA and to make the proteins incapable of further binding, even when the proteins are still in contact with the RNA. Still further, the reagent should disrupt any secondary or tertiary RNA structures, for example by chelation, so that the RNA can be used in subsequent processes and reactions.
[0004] United States Patent No. 6,875,857 of Simms ("Reagent for the Isolation of RNA,"
issued April 5, 2005) describes a reagent for extraction of RNA from cellular material, particularly plant cells, that includes one or ?
more nonionic detergents such as tergitol (tert.-octylphenoxy poly(oxyethylene)ethanol), one or more ionic detergents such as sodium dodecylbenzenesulfonate (SDS), one or more chelators such as EDTA, one or more reducing agents such as beta-mercaptoethanol, and one or more antibacterial agents such as sodium azide. While such a reagent appears to be effective for extracting RNA from plant cells and "other difficult materials," according to the patent, the reagent is a harsh reagent and, in addition, requires the subsequent use of an organic solvent such as chloroform to purify the RNA. Chloroform is a toxic material; and the use of chlorinated solvents in general are disfavored due to environmental considerations.
issued April 5, 2005) describes a reagent for extraction of RNA from cellular material, particularly plant cells, that includes one or ?
more nonionic detergents such as tergitol (tert.-octylphenoxy poly(oxyethylene)ethanol), one or more ionic detergents such as sodium dodecylbenzenesulfonate (SDS), one or more chelators such as EDTA, one or more reducing agents such as beta-mercaptoethanol, and one or more antibacterial agents such as sodium azide. While such a reagent appears to be effective for extracting RNA from plant cells and "other difficult materials," according to the patent, the reagent is a harsh reagent and, in addition, requires the subsequent use of an organic solvent such as chloroform to purify the RNA. Chloroform is a toxic material; and the use of chlorinated solvents in general are disfavored due to environmental considerations.
[0005] Other procedures in the prior art for isolating RNA from cellular material include those that utilize phenol, chloroform or isoamyl alcohol for extraction, as well as procedures that include the use of a chaotropic agent such as GITC (guanidine isothiocyanate) to precipitate nucleic acids. All of these procedures entail multiple steps, the use of hazardous chemicals, or both, and can take several hours to perform. One such procedure is disclosed in United States Pre-Grant Patent Application Publication No. US 2007/0015165 Al of Chen et al. (publication date January 18, 2007). Reagents for RNA extraction that have been commercially available include reagents bearing the product name AURUMTm, of Bio-Rad Laboratories, Inc., of Hercules, California, USA. The AURUM products contain GITC-type compounds. Another commercial reagent for RNA extraction is CytosAllTM (a product of Thermo Fisher Scientific, Inc., Waltham, Massachusetts, USA), which requires the addition of a protein-based RNAse inhibitor.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0006] It has now been discovered that RNA can be extracted to a high degree of efficiency from cellular material by use of a reagent that contains heparin, a reducing agent to reduce disulfide bonds, a chelating agent, a buffer, and an alkali metal halide. A
nonionic detergent can be included as a further but optional component. The efficiency in the use of this reagent arises from the fact that it does not require the use of organic solvents, and it can be performed in a relatively short period of time in comparison to the prior art.
In addition, the reagent is not chemically or physically harsh on the cellular material or to the user or the environment. The invention resides in the reagent itself as well as in the use of the reagent for the extraction of RNA from cellular material.
AND PREFERRED EMBODIMENTS
nonionic detergent can be included as a further but optional component. The efficiency in the use of this reagent arises from the fact that it does not require the use of organic solvents, and it can be performed in a relatively short period of time in comparison to the prior art.
In addition, the reagent is not chemically or physically harsh on the cellular material or to the user or the environment. The invention resides in the reagent itself as well as in the use of the reagent for the extraction of RNA from cellular material.
AND PREFERRED EMBODIMENTS
[0007] The heparin content of the reagent of the present invention is from about 1 pg/pt to about 10 pg/ L, of the reagent, preferably from about 1 pg/IAL to about 5 pg/IAL, and most preferably from about 1 pg/vil, to about 3 pg/4. Various forms of heparin, including heparin salts, can be used. The heparin stock used in preparing the reagent is preferably 98% or greater in purity.
[0008] The reducing agent included in the reagent can be any reducing agent that is known to reduce disulfide bonds in cellular proteins. Examples of such reducing agents are mercaptans, and preferred mercaptans are dithiothreitol, 0-mercaptoethanol, and tris(2-carboxyethyl)phosphine (TCEP). Dithiothreitol and 0-mercaptoethanol are particularly preferred. The concentration of reducing agent in the reagent in accordance with this invention is from about 1 mM to about 10 mM, preferably from about 1 mM to about 5 mM.
[0009] The chelating agent is included in any amount that will disrupt secondary and tertiary structures of RNA. In most cases, best results will be obtained with a chelating agent in a concentration ranging from about 0.3 mM to about 3 mM, and preferably about 1 mM.
Examples of suitable chelating agents are ethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid, citric acid, salicylic acid, salts of ethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid, citric acid, and salicylic acid, as well as phthalic acids, histidines, histidinol dihydrochlorides, and 8-hydroxyquinoline.
Ethylenediaminetetraacetic acid (EDTA) is preferred.
Examples of suitable chelating agents are ethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid, citric acid, salicylic acid, salts of ethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid, citric acid, and salicylic acid, as well as phthalic acids, histidines, histidinol dihydrochlorides, and 8-hydroxyquinoline.
Ethylenediaminetetraacetic acid (EDTA) is preferred.
[0010] The buffer is preferably one that maintains the pH of the reagent relatively close to physiological conditions, or from about 7.5 to about 8Ø Examples of suitable buffers are tris(hydroxymethypaminomethane (Tris base), tris(hydroxymethypaminomethane hydrochloride (Tris-HC1), bis(2-hydroxyethypiminotris-(hydroxymethypmethane (Bis-Tris base), bis(2-hydroxyethyDiminotris-(hydroxymethyl)methane hydrochloride (Bis-Tris-HC1), and N-2-hydroxyethyl-piperazine-N-2-ethanesulfonic acid (HEPES). The concentration of the buffer will vary with the actual buffer used, but in most cases, best results will be achieved with a buffer in a concentration of from about 1 mM to about 100 mM, preferably from about 10 mM to about 50 mM.
[0011] The alkali metal halide is included to maintain ionic strength. Alkali metal chlorides are preferred, particularly sodium, potassium or lithium chloride, which may be used individually or in mixtures of two or all three. For best results, the concentration of the alkali metal halide will range from about 1 niM to about 100 mM, preferably from about 10 mM to about 50 mM.
[0012] The reagent optionally contains one or more nonionic surfactants or detergents, for example, alkylphenoxy poly(oxyethylene)alkanols such as NP-40 or tergitol (IGEPALS).
Tergitols are generally tert.-octylphenoxy poly(oxyethylene)ethanols. Other suitable poly(oxyethylene)alkanols are TRITON products (octylphenol polyethoxylates) and TWEEN8 products (polyoxyethylene derivatives of various fatty acids). If present in the reagent, the nonionic detergent is preferably included in an amount of up to 2.5%, more preferably from about 0.5% to about 2.5%, and most preferably from about 0.5%
to about 2%, by volume.
Tergitols are generally tert.-octylphenoxy poly(oxyethylene)ethanols. Other suitable poly(oxyethylene)alkanols are TRITON products (octylphenol polyethoxylates) and TWEEN8 products (polyoxyethylene derivatives of various fatty acids). If present in the reagent, the nonionic detergent is preferably included in an amount of up to 2.5%, more preferably from about 0.5% to about 2.5%, and most preferably from about 0.5%
to about 2%, by volume.
[0013] The cellular material from which the reagents of this invention can be used effectively to extract RNA include any individual biological cells that contain RNA, and any tissue or other cell masses that include such cells. RNA can thus be extracted from animal cellular material, including mammalian cellular material, by this invention.
[0014] The reagents of this invention do not require the ionic (cationic or anionic) detergents cited in the Simms patent referenced above as "secondary" or "helper" detergents, and preferred reagent compositions in accordance with this invention do not contain these detergents. By avoiding these detergents, the reagent can extract RNA from cellular material under conditions that are more gentle than those that exist when these detergents are present.
The reagents of this invention are also effective without the use of an organic solvent for extraction of the supernatant. Such use of an organic solvent, notably chloroform, is cited in the Simms patent referenced above. Furthermore, the reagents of this invention do not require the use of a chaotrope or of silica binding. Without these additional reagents or procedural steps, an extraction process using a reagent of this invention can be performed in relatively few steps and can be complete in only about ten minutes.
EXAMPLES
The reagents of this invention are also effective without the use of an organic solvent for extraction of the supernatant. Such use of an organic solvent, notably chloroform, is cited in the Simms patent referenced above. Furthermore, the reagents of this invention do not require the use of a chaotrope or of silica binding. Without these additional reagents or procedural steps, an extraction process using a reagent of this invention can be performed in relatively few steps and can be complete in only about ten minutes.
EXAMPLES
[0015] The following general procedure is used to extract RNA from a cellular material with reagents of this invention:
[0016] The chosen cells are washed with PBS solution (50 mM potassium phosphate and 150 mM NaCl; pH 7.2) with spinning (500 rcf at 4 C) and are resuspended in PBS
to the desired concentration (1 -1000 cells/1AL as the dynamic range for lysis). The cells are then pelletized and the PBS solution removed an replaced with an equal volume of an RNA
extraction reagent according to the invention, by adding the reagent directly to the pelletized cells. The resulting mixture is vortexed for about 30 seconds, then spun for 3 minutes at 5000 rcf at room temperature to pelletize the cell nuclei. The supernatant liquid, which 5 contains the extracted RNA, is then removed and is ready for downstream use without further extraction or processing.
to the desired concentration (1 -1000 cells/1AL as the dynamic range for lysis). The cells are then pelletized and the PBS solution removed an replaced with an equal volume of an RNA
extraction reagent according to the invention, by adding the reagent directly to the pelletized cells. The resulting mixture is vortexed for about 30 seconds, then spun for 3 minutes at 5000 rcf at room temperature to pelletize the cell nuclei. The supernatant liquid, which 5 contains the extracted RNA, is then removed and is ready for downstream use without further extraction or processing.
[0017] Reagents in accordance with this invention were assessed by their ability to lyse cells efficiently within the range of 1-1000 cells/pl. Success was measured by evaluating the linearity of the standard curve with respect to cell concentrations across three logs using quantitative RT-PCR. The presence of genomic DNA in the lys ate was also evaluated.
There had to be at least 25-fold less genomic DNA for a given gene than its mRNA, as measured by quantitative RT-PCR, for the formulation to be considered successful.
There had to be at least 25-fold less genomic DNA for a given gene than its mRNA, as measured by quantitative RT-PCR, for the formulation to be considered successful.
[0018] Tables 1, 2, and 3 below show compositions of reagent solutions according to the invention that were tested in extracting RNA from HeLa cells, and deemed successful by the above standards. The solutions contained heparin, EDTA, and dithiothreitol (DTT) in the indicated amounts, and other ingredients as specified.
Reagents That Successfully Extracted RNA from HeLa Cells Type 1: EDTA, DTT, and Heparin in Amounts shown, plus 10 mM Tris, pH 7.5; 10 mM
NaCl; 1.25 v/v % NP-40 detergent Reagent No. pH EDTA, mM DTT, mM Heparin, pg/pL
1 7.5 1 1 1 2 7.5 1 1 5 3 7.5 1 1 10 4 7.5 1 5 1 5 7.5 1 5 5 6 7.5 1 5 10 7 7.5 1 10 1 8 7.5 1 10 5 9 7.5 1 10 10 Reagents That Successfully Extracted RNA from HeLa Cells Type 2: EDTA, DTT, and Heparin in Amounts shown, plus 10 mM Tris, pH 8.0; 10 mM
NaCl; 1.25 v/v % NP-40 detergent Reagent No. pf EDTA, mM DTT, mM Heparin, pg/pt 8.0 1 1 10 11 8.0 1 5 1 12 8.0 1 5 5 13 8.0 1 5 10 14 8.0 1 10 1 8.0 1 10 5 16 8.0 1 10 10 17 8.0 1 1 0 18 8.0 1 1 1 Reagents That Successfully Extracted RNA from HeLa Cells Type 3: EDTA, DTT, and Heparin in Amounts shown, plus 10 mM Tris, pH 8.0; 50 mM
5 NaCl; 1.25 v/v % NP-40 detergent Reagent No. pf EDTA, mM DTT, mM Heparin, pg/pt 19 8.0 1 1 0 8.0 1 1 1 21 8.0 1 1 5 22 8.0 1 1 10 23 8.0 1 5 1 24 8.0 1 5 5 8.0 1 5 10 26 8.0 1 10 1 27 8.0 1 10 5 28 8.0 1 10 10 [0019] In the claim or claims appended hereto, the term "a" or "an" is intended to mean "one or more." The term "comprise" and variations thereof such as "comprises"
and "comprising," when preceding the recitation of a step or an element, are intended to mean that the addition of further steps or elements7is optional and not excluded.
Any discrepancy between any reference material cited herein and an explicit teaching of this specification is intended to be resolved in favor of the teaching in this specification. This includes any discrepancy between an art-understood definition of a word or phrase and a definition explicitly provided in this specification of the same word or phrase.
Reagents That Successfully Extracted RNA from HeLa Cells Type 1: EDTA, DTT, and Heparin in Amounts shown, plus 10 mM Tris, pH 7.5; 10 mM
NaCl; 1.25 v/v % NP-40 detergent Reagent No. pH EDTA, mM DTT, mM Heparin, pg/pL
1 7.5 1 1 1 2 7.5 1 1 5 3 7.5 1 1 10 4 7.5 1 5 1 5 7.5 1 5 5 6 7.5 1 5 10 7 7.5 1 10 1 8 7.5 1 10 5 9 7.5 1 10 10 Reagents That Successfully Extracted RNA from HeLa Cells Type 2: EDTA, DTT, and Heparin in Amounts shown, plus 10 mM Tris, pH 8.0; 10 mM
NaCl; 1.25 v/v % NP-40 detergent Reagent No. pf EDTA, mM DTT, mM Heparin, pg/pt 8.0 1 1 10 11 8.0 1 5 1 12 8.0 1 5 5 13 8.0 1 5 10 14 8.0 1 10 1 8.0 1 10 5 16 8.0 1 10 10 17 8.0 1 1 0 18 8.0 1 1 1 Reagents That Successfully Extracted RNA from HeLa Cells Type 3: EDTA, DTT, and Heparin in Amounts shown, plus 10 mM Tris, pH 8.0; 50 mM
5 NaCl; 1.25 v/v % NP-40 detergent Reagent No. pf EDTA, mM DTT, mM Heparin, pg/pt 19 8.0 1 1 0 8.0 1 1 1 21 8.0 1 1 5 22 8.0 1 1 10 23 8.0 1 5 1 24 8.0 1 5 5 8.0 1 5 10 26 8.0 1 10 1 27 8.0 1 10 5 28 8.0 1 10 10 [0019] In the claim or claims appended hereto, the term "a" or "an" is intended to mean "one or more." The term "comprise" and variations thereof such as "comprises"
and "comprising," when preceding the recitation of a step or an element, are intended to mean that the addition of further steps or elements7is optional and not excluded.
Any discrepancy between any reference material cited herein and an explicit teaching of this specification is intended to be resolved in favor of the teaching in this specification. This includes any discrepancy between an art-understood definition of a word or phrase and a definition explicitly provided in this specification of the same word or phrase.
Claims (18)
1. A reagent for extracting RNA from cellular material, said reagent comprising:
(a) from about 1 pg/µL, to about 10 pg/µL heparin;
(b) from about 1 mM to about 10mM of a reducing agent effective to reduce disulfide bonds in cellular proteins;
(c) a chelating agent in an amount sufficient to disrupt RNA secondary and tertiary structures;
(d) from about 1 mM to about 100mM of a buffer selected from the group consisting of Tris base, Tris-HCl, Bis-Tris base, Bis-Tris-HCl, and HEPES; and (e) from about 1 mM to about 100 mM of an alkali metal halide said reagent being devoid of chlorinated solvents.
(a) from about 1 pg/µL, to about 10 pg/µL heparin;
(b) from about 1 mM to about 10mM of a reducing agent effective to reduce disulfide bonds in cellular proteins;
(c) a chelating agent in an amount sufficient to disrupt RNA secondary and tertiary structures;
(d) from about 1 mM to about 100mM of a buffer selected from the group consisting of Tris base, Tris-HCl, Bis-Tris base, Bis-Tris-HCl, and HEPES; and (e) from about 1 mM to about 100 mM of an alkali metal halide said reagent being devoid of chlorinated solvents.
2. The reagent of claim 1 wherein said heparin constitutes from about 1 pg/µL, to about 3 pg/µL, of said reagent.
3. The reagent of claim 1 wherein said reducing agent constitutes from about 1 mM to about 5 mM of said reagent.
4. The reagent of claim 1 wherein said reducing agent is a member selected from the group consisting of dithiothreitol, .beta.-mercaptoethanol and tris(2-carboxyethyl) phosphine.
5. The reagent of claim 1 wherein said chelating agent is a member selected from the group consisting of ethylenediaminetetraacetic acid;
ethylene glycol tetraacetic acid; citric acid; salicylic acid; salts of ethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid, citric acid, and salicylic acid; a phthalic acid; a histidine; a histidinol dihydrochloride; and 8-hydroxyquinoline.
ethylene glycol tetraacetic acid; citric acid; salicylic acid; salts of ethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid, citric acid, and salicylic acid; a phthalic acid; a histidine; a histidinol dihydrochloride; and 8-hydroxyquinoline.
6. The reagent of claim 1 wherein said chelating agent is ethylenediaminetetraacetic acid.
7. The reagent of claim 1 wherein said chelating agent constitutes from about 0.3 mM to about 3 mM of said reagent.
8. The reagent of claim 1 wherein said buffer constitutes an amount of said reagent that maintains the pH of said reagent at from about 7.5 to about 8Ø
9. The reagent of claim 1 wherein said alkali metal halide is selected from the group consisting of sodium chloride, potassium chloride, and lithium chloride.
10. The reagent of claim 1 wherein said alkali metal halide is an alkali metal chloride and constitutes from about 10 mM to about 50mM of said reagent.
11. The reagent of claim 1 further comprising a nonionic detergent in an amount less than or equal to about 2.5% by volume.
12. The reagent of claim 1 wherein said reagent is devoid of cationic detergents and anionic detergents.
13. A method for extracting RNA from cellular material, said method comprising contacting said cellular material with the reagent of claim 1 to extract said RNA
into a supernatant, and recovering said supernatant from the remainder of said cellular material.
into a supernatant, and recovering said supernatant from the remainder of said cellular material.
14. The method of claim 13 performed without extracting said supernatant with an organic solvent.
15. The method of claim 13 performed without treatment of said cellular material with an enzyme to remove genomic DNA therefrom.
16. The method of claim 13 performed without heating of said cellular material to denature proteins therein.
17. The method of claim 13 wherein said heparin constitutes from about 1 pg/ L to about 3 pg/µL, of said reagent, said reducing agent constitutes from about 1 mM
to about 5 mM of said reagent, said chelating agent is ethylenediaminetetraacetic acid and constitutes from about 0.3 mM to about 3 mM of said reagent, said buffer constitutes an amount of said reagent that maintains the pH of said reagent at from about 7.5 to about 8.0, and said alkali metal halide constitutes from about 10 mM to about 50 mM of said reagent.
to about 5 mM of said reagent, said chelating agent is ethylenediaminetetraacetic acid and constitutes from about 0.3 mM to about 3 mM of said reagent, said buffer constitutes an amount of said reagent that maintains the pH of said reagent at from about 7.5 to about 8.0, and said alkali metal halide constitutes from about 10 mM to about 50 mM of said reagent.
18. The method of claim 13 wherein said reagent further comprises a nonionic detergent in an amount less than or equal to about 2.5% by volume and is devoid of ionic detergents.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6115908P | 2008-06-13 | 2008-06-13 | |
US61/061,159 | 2008-06-13 | ||
US12/479,484 | 2009-06-05 | ||
US12/479,484 US8357672B2 (en) | 2008-06-13 | 2009-06-05 | Cell lysis reagent for isolation of RNA |
PCT/US2009/046832 WO2009152204A1 (en) | 2008-06-13 | 2009-06-10 | Cell lysis reagent for isolation of rna |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2728232A1 CA2728232A1 (en) | 2009-12-17 |
CA2728232C true CA2728232C (en) | 2014-09-30 |
Family
ID=41417100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2728232A Active CA2728232C (en) | 2008-06-13 | 2009-06-10 | Cell lysis reagent for isolation of rna |
Country Status (5)
Country | Link |
---|---|
US (1) | US8357672B2 (en) |
EP (1) | EP2300488B1 (en) |
JP (1) | JP5426668B2 (en) |
CA (1) | CA2728232C (en) |
WO (1) | WO2009152204A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3124596A1 (en) * | 2009-09-16 | 2017-02-01 | Life Technologies Corporation | Lysis buffers for extracting nucleic acids |
US9057673B2 (en) * | 2012-08-24 | 2015-06-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of preparing RNA from ribonuclease-rich sources |
US10436680B2 (en) | 2013-10-15 | 2019-10-08 | Kianoosh Peyvan | Capture, disruption, and extraction apparatus and method |
EP3408389B1 (en) | 2016-01-29 | 2021-03-10 | Purigen Biosystems, Inc. | Isotachophoresis for purification of nucleic acids |
US11041150B2 (en) | 2017-08-02 | 2021-06-22 | Purigen Biosystems, Inc. | Systems, devices, and methods for isotachophoresis |
WO2019116234A1 (en) | 2017-12-12 | 2019-06-20 | Nestec S.A. | Methods for determining microbiome ribosomal rna composition changes |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58116498A (en) | 1981-12-28 | 1983-07-11 | Takeda Chem Ind Ltd | Novel messenger rna coding il-2, its preparation and preparation of il-2 using it |
US5128247A (en) | 1989-08-14 | 1992-07-07 | Board Of Regents, The University Of Texas System | Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources |
US20040091923A1 (en) * | 1993-07-23 | 2004-05-13 | Bio-Rad Laboratories, Inc. | Linked linear amplification of nucleic acids |
GB9606062D0 (en) * | 1996-03-22 | 1996-05-22 | Zeneca Ltd | Promoters |
JP4519247B2 (en) * | 2000-03-09 | 2010-08-04 | シスメックス株式会社 | Nucleic acid extraction and purification reagents |
US6875857B2 (en) * | 2001-01-16 | 2005-04-05 | Invitrogen Corporation | Reagent for the isolation of RNA |
US7745180B2 (en) | 2002-04-24 | 2010-06-29 | Hitachi Chemical Co., Ltd. | Device and method for high-throughput quantification of mRNA from whole blood |
US20070015165A1 (en) | 2005-07-13 | 2007-01-18 | Sigma-Aldrich Co. | Method for the isolation of RNA from biological sources |
US20080003575A1 (en) | 2006-06-28 | 2008-01-03 | Sigma-Aldrich Co. | Methods and composition for RNA extraction |
-
2009
- 2009-06-05 US US12/479,484 patent/US8357672B2/en active Active
- 2009-06-10 JP JP2011513650A patent/JP5426668B2/en active Active
- 2009-06-10 WO PCT/US2009/046832 patent/WO2009152204A1/en active Application Filing
- 2009-06-10 EP EP09763494.3A patent/EP2300488B1/en active Active
- 2009-06-10 CA CA2728232A patent/CA2728232C/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8357672B2 (en) | 2013-01-22 |
JP2011524360A (en) | 2011-09-01 |
EP2300488A4 (en) | 2012-04-04 |
JP5426668B2 (en) | 2014-02-26 |
WO2009152204A1 (en) | 2009-12-17 |
EP2300488B1 (en) | 2014-03-19 |
CA2728232A1 (en) | 2009-12-17 |
US20090317894A1 (en) | 2009-12-24 |
EP2300488A1 (en) | 2011-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10947527B2 (en) | Compositions and methods for purifying nucleic acids from stabilization reagents | |
CA2728232C (en) | Cell lysis reagent for isolation of rna | |
EP1354036B1 (en) | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases | |
EP1773996B9 (en) | Compositions and methods for using a solid support to purify dna | |
AU759401B2 (en) | Improved method for the isolation of nucleic acid | |
EP2094846B1 (en) | Use of tde for the isolation of nucleic acids | |
WO2021122855A1 (en) | Method for enriching vesicular rna | |
US20090130687A1 (en) | Formulations and method isolating nucleic acids from arbitrary complex starting materials and subsequent complex genetic materials | |
EP2126074B1 (en) | Use of acetals for the isolation of nucleic acids | |
EP1992693B1 (en) | Absorption of nucleic acids to solid phases under low-salt conditions | |
US20170051333A1 (en) | Compositions for cell lysis and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |